CMB International Securities  Equity Research Company Update
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
China Healthcare Sector
Jill Wu CFA
Sam HU PhD
Mkt Cap (RMB mn)
Avg 3mths to (RMB mn)
52W HighLow (RMB)
Total Issued Shares (mn)
Source Bloomberg
Shareholding Structure
A-share public shareholders
H-share public shareholders
Source Bloomberg
Source Bloomberg
12-mth price performance
Source Bloomberg
Auditor Deloitte Touche Tohmatsu
Strong core business growth  26
Strengthening leading position in
global CROCDMO industry  13
Please cast your valuable vote
for CMBIS research team in the
2020 Asiamoney Brokers Poll
SHSZ300 (rebased)
BUY (Maintain)
(Previous TP
RMB11832)
UpDownside
Strong growth not interrupted by COVID-19 pandemic WuXi AppTec
reported 1H20 revenue of RMB723bn up 23% YoY largely inline with our
estimate Non-IFRS net profit was up 29% YoY to RMB152bn Attributable
net profit surged 62% YoY to RMB172bn mainly due to the RMB408mn
Fast expanding customer base during COVID-19 pandemic In 1H20
WuXi AppTec added c 600 new customers which contributed 55% of the
Companys total revenue WuXi AppTec has provided services to a wide
total revenue in 1H20
CDMO revenue grew 26% YoY to RMB216bn contributing 30% of the total
revenue Thanks to follow-the-molecule strategy the Company added 269
new molecules into its CDMO pipeline The CDMO business has rich
II projects and 861 early-stage projects In order to meet the strong demand
the Company boosted its annual manufacturing capacity of high potency APIs
to 100 kg level by Jun 2020 and will further expand its CDMO capacity
DDSU projects allows the Company to share profit from innovative
drugs In 1H20 WuXi AppTec has submitted 13 INDs for DDUS projects
accounting for 19% of innovative small molecule IND filings accepted by the
filings and 66 clinical approvals In addition 84 DDSU projects are in
discovery or preclinical phase
We lifted SOTP-based TP from RMB11832 to RMB13198 to reflect
strong long-term growth outlook for WuXi AppTec We forecast WuXi
AppTecs adjusted Non-IFRS net profit to grow by 27%33%29% YoY in
FY20E21E22E respectively and attributable net profit to increase
73%24%29% YoY in FY20E21E22E Moreover WuXi AppTec
which will bring significant investment gains over the long term
Catalysts 1) Higher-than-expected earnings growth 2) Overseas
acquisitions Risk Operation disrupted by the COVID-19 Pandemic
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
YoY growth (%)
YoY growth (%)
Change (%)
Consensus EPS (RMB)
Net gearing (%)
Source Company data Wind CMBIS estimates
WuXi AppTec (603259 CH)
Enhance leading position amid COVID-19 pandemic
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 1 CMBIS earnings revisions
Source Company data CMBIS estimates
Figure 2 SOTP valuation
Attributable Non-IFRS net profit (RMB mn)
PE multiple of core business
Valuation of CROCDMO business (RMB mn)
Fair value of other non-current financial assets (RMB mn)
PB multiple of investment business
Valuation of investment business (RMB mn)
SOTP valuation (RMB mn)
 of shares
Target price (RMB per share)
Source CMBIS estimates
Figure 3 Peers valuation
(LC) (US mn) FY20E FY21E FY22E FY20E FY21E FY20E FY21E FY20E FY21E
WuXi Biologics 2269 HK
603259 CH BUY
300347 CH BUY
300759 CH NR
603127 CH NR
Asymchem Lab 002821 CH NR
Source Bloomberg CMBIS estimates as at 14 Aug 2020
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E
China-based lab services
8240 10547 13289  Depreciation and amortization
CMOCDMO services
7833  Change in working capital
US-based laboratory services
2862  Investment loss (gain)
Clinical research  other
2277  Other operating activities
28  Net cash from operating
Acquisition of subsidiaries
(58)  Other investing activities
Selling  distribution expenses
(841)  Net cash from investing
Administrative expenses
RD expenses
(928) (1130)  Net proceeds from shares issued
5425  Net borrowings
Acquisition of non-controlling
Finance costs net
0  Dividends and interests paid
80  Other financing activities
Net gain from FV changes
456  Net cash from financing
Pre-tax profit
(918)  Net change in cash
(41)  Cash at the beginning of the year
5163  Cash at the end of the year
YE 31 Dec (RMB mn)
FY18A FY19A FY20E FY21E FY22E  YE 31 Dec
FY18A FY19A FY20E FY21E FY22E
Non-current assets
6732  China-based lab services
705  CMOCDMO services
9129 11165  US-based laboratory services
Clinical research and other
Other non-current assets
5138  Others
11807 12663 15143 16093 18406  Profit  loss ratios (%)
8158  Gross margin
2762  EBITDA margin
Trade and bills receivables
4754  Pre-tax margin
Prepayments deposits
and other receivables
123  Net margin
2609  Effective tax rate
7012  Balance sheet ratios
104  Current ratio (x)
Trade and other payables
2470  Trade receivables turnover days
Other current liabilities
4438  Trade payables turnover days
Net debt to total equity ratio (%) Net cash
1 Net cash Net cash Net cash
Non-current liabilities
762  Returns (%)
Other non-current liabilities
2933  ROE
195  Per share
Shareholders equity
BVPS (RMB)
Source Company data CMBIS estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
in this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIS
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Securities Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Securities Limited (CMBIS) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary
of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIS
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in
the report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIS solely for the purpose of supplying information to the clients of CMBIS or
its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIS nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the information contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIS may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIS does or seeks to have investment banking or other business relationships with
and CMBIS will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIS
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIS
For recipients of this document in the United States
This report is intended for distribution in the United States to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange
Act of 1934 and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this research
report by its acceptance hereof represents and agrees that it shall not distribute or provide this research report to any other person
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as
defined in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced
by its respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers
Regulations Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined
in the Securities and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the
extent required by law Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report